AcuFocus has announced a $4.1 million round of debt funding, according to a regulatory filing. The company makes the Kamra eye inlay for treating nearsightedness (presbyopia), potentially eliminating the need for reading glasses as people age.
The Kamra inlay is microscopically small, and it rests in the cornea. The name of the product is appropriate because it actually does work like a camera lens. The aperture allows light to go directly into the eye and reach the back of the eye, which then enhances a person’s range of vision.
The Hidden Administrative Tasks Draining Small Practices
Small practices play a critical role in healthcare delivery, but they cannot continue to absorb ever-increasing administrative demands without consequences.
A total of 8,400 microscopic openings surround the central aperture to allow oxygen and nutrients to flow through the eye and ensure cornea health.
The company landed CE Mark approval in 2014 after it raised $21 million, and it was approved in the U.S. in 2015 and is currently commercially available. AcuFocus is backed by HealthCare Royalty Partners, SV Life Sciences, Versant Ventures, Carlyle Group, Accuitive Medical Ventures and Medtronic.
Another company, ReVision Optics, has also created a similar inlay, which was backed by Johnson & Johnson Development Corp back in 2013.